[1] 彭宇.晚期非小细胞肺癌不同含铂两药方案一线化疗预后因素的分析[J].第三军医大学学报,2014,36(16):1703-1708. [2] 田莉莉,高山,崔晓柄.华赡素注射液对人肝癌HepG-2细胞增殖与凋亡及拓扑异构酶的影响[J].中国临床药理学杂志,2013,29(7):530-533. [3] Buccheri G,Ferrigno D,Tamburini M.Karnofsky and ECOG performance status scoring in lung cancer: a prospective,longitudinal study of 536 patients from a single institution[J].Eur J Cancer,1996,32A (7):1135-1141. [4] Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216. [5] Sohn J,Liu S,Parinyanitikul N,et al.cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer[J].J Cancer,2014,5(9):745-753. [6] 刘润华,李修金.DP与GP方案治疗晚期非小细胞肺癌的近期疗效观察[J].实用癌症杂志,2016,31(6):1039-1040. [7] 田丽,王翠英.鸦胆子油乳注射液联合GP方案治疗晚期非小细胞肺癌临床研究[J].中医学报,2017,3(3):339-341. [8] 汤伟,胡凯文.华蟾素抗恶性肿瘤的临床应用进展[J].中医药导报,2017,23(12):41-44.
2019, Vol. 36 
